Difficult to control atopic dermatitis

World Allergy Organization Journal

Johannes Ring⁹  Stefania Seidenari⁷  Jann Lübbe²  Francesca Giusti⁷  Anne-Marie Calza²  Mette Deleuran⁵  Ake Svensson⁸  Carlo Gelmetti⁴  Arnold Oranje^1,11  Thomas Werfel⁶  Alain Taïeb³  Dagmar Simon^1,10  Andreas Wollenberg¹  Ulf Darsow⁹ 

[1] Department of Dermatology and Allergy, Ludwig-Maximilians-University Munich, Munich, Germany;Clinique de Dermatologie, Hôpital Cantonal Universitaire, Genève, Suisse, Switzerland;Service de Dermatologie, Hopital St André, Bordeaux, France;Department of Pathophysiology and Transplantation, University of Milan, Ospedale Maggiore Policlinico, Milan, Italy;Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark;Hautklinik Linden, Deptartment of Dermatology MHH, Hannover, Germany;Department of Dermatology, University of Modena and Reggio Emilia, Modena, Italy;Department of Dermatology, University Hospital UMAS, Malmö, Sweden;ZAUM – Center for Allergy and Environment, Munich, Germany;Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland;Department of Pediatrics (Pediatric Dermatology Unit), ERASMUS MC, Rotterdam, The Netherlands

关键词: Guideline;    Therapy;    Eczema;    Atopic dermatitis;   

Others  :  804140
DOI  :  10.1186/1939-4551-6-6

 received in 2012-11-20, accepted in 2013-03-04,  发布年份 2013

【 摘 要 】

Difficult to control atopic dermatitis (AD) presents a therapeutic challenge and often requires combinations of topical and systemic treatment. Anti-inflammatory treatment of severe AD most commonly includes topical glucocorticosteroids and topical calcineurin antagonists used for exacerbation management and more recently for proactive therapy in selected cases. Topical corticosteroids remain the mainstay of therapy, the topical calcineurin inhibitors tacrolimus and pimecrolimus are preferred in certain locations. Systemic anti-inflammatory treatment is an option for severe refractory cases. Microbial colonization and superinfection contribute to disease exacerbation and thus justify additional antimicrobial / antiseptic treatment. Systemic antihistamines (H1) may relieve pruritus but do not have sufficient effect on eczema. Adjuvant therapy includes UV irradiation preferably of UVA1 wavelength. “Eczema school” educational programs have been proven to be helpful.

【 授权许可】

   
2013 Darsow et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Ring J, Przybilla B, Ruzicka T (Eds): Handbook of atopic eczema. 2nd edition. Heidelberg: Springer; 2006.
• [2]Ring J, Alomar A, Bieber T, Deleuran M, Fink-Wagner A, Gelmetti C, Gieler G, Lipozencic J, Luger T, Oranje AP, Schäfer T, Schwennesen T, Seidenari S, Simon D, Ständer S, Stingl G, Szalai S, Szepietowski JC, Taïeb A, Werfel T, Wollenberg A, Darsow U: Guidelines for Treatment of Atopic Eczema (Atopic Dermatitis) Part I. J Eur Acad Dermatol Venereol 2012, 26:1045-1060.
• [3]Manzini BM, Ferdani G, Simonetti V, Donini M, Seidenari S: Contact sensitization in children. Contact Dermatitis 1998, 15:12-17.
• [4]Mortz CG, Andersen KE: Allergic contact dermatitis in children and adolescents. Contact Dermatitis 1999, 41:121-130.
• [5]Devillers AC, Oranje AP: Efficacy and safety of 'wet-wrap' dressings as an intervention treatment in children with severe and/or refractory atopic dermatitis: a critical review of the literature. Br J Dermatol 2006, 154:579-585.
• [6]Schnopp C, Holtmann C, Stock S, Remling R, Fölster-Holst R, Ring J, Abeck D: Topical steroids under wet-wrap dressings in atopic dermatitis-a vehicle-controlled trial. Dermatology 2002, 204:56-59.
• [7]Wollenberg A, Bieber T: Proactive therapy of atopic dermatitis -an emerging concept. Allergy 2009, 64:276-278.
• [8]Van der Meer JB, Glazenburg EJ, Mulder PG, Eggink HF, Coenraads PJ: The management of moderate to severe atopic dermatitis in adults with topical fluticasone propionate. The Netherlands Adult Atopic Dermatitis Study Group. Br J Dermatol 1999, 140:1114-1121.
• [9]Feiwel M, Munro D, James V: Effect of topically applied 0.1% betamethasone valerate ointment on the adrenal function of children. In Thirteenth congress of International Dermatology. Berlin: Springer; 1968:202-204.
• [10]Walsh P, Aeling J, Huff L, Weston W: Hypothalamus-pituitary-adrenal axis suppression by superpotent topical steroids. J Am Acad Dermatol 1993, 29:501-503.
• [11]Bornhövd E, Burgdorf WHC, Wollenberg A: Macrolactam immunomodulators for topical treatment of inflammatory skin diseases. J Am Acad Dermatol 2001, 45:736-743.
• [12]Ruzicka T, Bieber T, Schöpf E, Rubins A, Dobozy A, Bos J: A short-term trial of tacrolimus ointment for atopic dermatitis. N Engl J Med 1997, 337:816-821.
• [13]Van Leent EJ, Graber M, Thurston M, Wagenaar A, Spuls PI, Bos JD: Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. Arch Dermatol 1998, 134:805-809.
• [14]Reitamo S, Wollenberg A, Schöpf E, Perrot JL, Marks R, Ruzicka T: Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. Arch Dermatol 2000, 136:999-1006.
• [15]Meurer M, Fölster-Holst R, Wozel G, Weidinger G, Jünger M, Bräutigam M: Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology 2002, 205:271-277.
• [16]Wollenberg A, Reitamo S, Girolomoni G, Lahfa M, Ruzicka T, Healy E, Giannetti A, Bieber T, Vyas J, Deleuran M: Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment. Allergy 2008, 63:742-750.
• [17]Thaci D, Reitamo S, Gonzalez Ensenat MA, Moss C, Boccaletti V, Cainelli T, Van Der Valk P, Buckova H, Sebastian M, Schuttelaar M, Ruzicka T: Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study. Br J Dermatol 2008, 159:1348-1356.
• [18]Reitamo S, Rustin M, Ruzicka T, Cambazard F, Kalimo K, Friedmann P: Efficacy and safety of tacrolimus ointment compared with hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol 2002, 109:547-555.
• [19]Luger T, Van Leent E, Graeber M, Hedgecock S, Thurston M, Kandra A: SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br J Dermatol 2001, 144:788-794.
• [20]Diepgen TL: Long-term treatment with cetirizine of infants with atopic dermatitis: a multi-country, double-blind, randomized, placebo-controlled trial (the ETAC trial) over 18 months. Pediatr Allergy Immunol 2002, 13:278-286.
• [21]De Benedetto A, Agnihothri R, McGirt LY, Bankova LG, Beck LA: Atopic dermatitis: a disease caused by innate immune defects. J Invest Dermatol 2009, 129:14–30-22.
• [22]Lübbe J: Secondary infections in patients with atopic dermatitis. Am J Clin Dermatol 2003, 4:641-654.
• [23]Shah M, Mohanraj M: High levels of fusidic acid resistant Staphylococcus aureus in dermatology patients. Br J Dermatol 2003, 148:1018-1020.
• [24]Niebuhr M, Mai U, Kapp A, Werfel T: Antibiotic treatment of cutaneous infections with Staphylococcus aureus in patients with atopic dermatitis: current antimicrobial resistances and susceptibilities. Exp Dermatol 2008, 17:953-957.
• [25]Bunikowski R, Mielke M, Skarabis H, Worm M, Anagnostopoulos I, Kolde G: Evidence for a disease-promoting effect of staphylococcus aureus-derived exotoxins in atopic dermatitis. J Allergy Clin Immunol 2000, 105:814-819.
• [26]Zollner T, Wichelhaus T, Hartung A, Von Mallinckrodt C, Wagner T, Brade V: Colonization with superantigen-producing staphylococcus aureus is associated with increased severity of atopic dermatitis. Clin Exp Allergy 2000, 30:994-1000.
• [27]Hauser C, Wuethrich B, Matter L: Staphylococcus aureus skin colonization in atopic dermatitis. Dermatologica Helvetica 1985, 170:35.
• [28]Breuer K, Haussler S, Kapp A, Werfel T: Staphylococcus aureus: colonizing features and influence of an antibacterial treatment in adults with atopic dermatitis. Br J Dermatol 2002, 147:55-61.
• [29]Lintu P, Savolainen J, Kortekangas-Savolainen O, Kalimo K: Systemic ketoconazole is an effective treatment of atopic dermatitis with IgE-mediated hypersensitivity to yeasts. Allergy 2001, 56:512-517.
• [30]Mayser P, Kupfer J, Nemetz D, Schäfer U, Nilles M, Hort W, Gieler U: Treatment of head and neck dermatitis with ciclopiroxolamine cream - results of a double-blind, placebo-controlled study. Skin Pharmacol Physiol 2006, 19:153-158.
• [31]Williams HC, Grindlay DJ: What's new in atopic eczema? An analysis of the clinical significance of systematic reviews on atopic eczema published in 2006 and 2007. Clin Exp Dermatol 2008, 33:685-688.
• [32]Akhavan A, Rudikoff D: Atopic dermatitis: systematic immunosuppressive therapy. Semin Cutan Med Surg 2008, 27:151-155.
• [33]Berth-Jones L, Finlay A, Zaki I, Tan B, Goodyear H, Lewis-Jones S: Ciclosporin in severe childhood atopic dermatitis: a multicentre study. J Am Acad Dermatol 1996, 34:1016-1021.
• [34]Van Joost T, Heule F, Korstanje M, Van-den-Broek M, Stenveld H, Van-Vloten W: Ciclosporin in atopic dermatitis: a multicentre, placebo-controlled study. Br J Dermatol 1994, 130:634-640.
• [35]Murphy LA, Atherton D: A retrospective evaluation of azathioprine in severe childhood atopic eczema, using thiopurine methyltransferase levels to exclude patients at high risk of myelosuppression. Br J Dermatol 2002, 147:308-315.
• [36]Berth-Jones J, Takwale A, Tan E, Barclay G, Agarwal S, Ahmed I: Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial. Br J Dermatol 2002, 147:324-330.
• [37]Grundmann-Kollmann M, Podda M, Ochsendorf F, Boehncke W-H, Kaufmann R, Zollner T: Mycophenolate mofetil is effective in the treatment of atopic dermatitis. Arch Dermatol 2001, 137:870-873.
• [38]Heller M, Shin HT, Orlow SJ, Schaffer JV: Mycophenolate mofetil for severe childhood atopic dermatitis: experience in 14 patients. Br J Dermatol 2007, 157:127-132.
• [39]Murray ML, Cohen JB: Mycophenolate mofetil therapy for moderate to severe atopic dermatitis. Clin Exp Dermatol 2007, 32:23-27.
• [40]Goujon C, Berard F, Dahel K, Guillot I, Hennino A, Nosbaum A, Saad N, Nicolas JF: Methotrexate for the treatment of adult atopic dermatitis. Eur J Dermatol 2006, 16:155-158.
• [41]Simon D, Wittwer J, Kostylina G, Buettiker U, Simon HU, Yawalkar N: Alefacept (lymphocyte function-associated molecule 3/IgG fusion protein) treatment for atopic eczema. J Allergy Clin Immunol 2008, 122:423-424.
• [42]Moul DK, Routhouska SB, Robinson MR, Korman NJ: Alefacept for moderate to severe atopic dermatitis: a pilot study in adults. J Am Acad Dermatol 2008, 58:984-989.
• [43]Simon D, Hösli S, Kostylina G, Yawalkar N, Simon HU: Anti-CD20 (rituximab) treatment improves atopic eczema. J Allergy Clin Immunol 2008, 121:122-128.
• [44]Darsow U, Wollenberg A, Simon D, Taïeb A, Werfel T, Oranje A, Gelmetti C, Svensson A, Deleuran M, Calza AM, Giusti F, Lübbe J, Seidenari S, Ring J for the European Task Force on Atopic Dermatitis / EADV Eczema Task Force: ETFAD / EADV Eczema Task Force 2009 position paper on diagnosis and treatment of atopic dermatitis. J Eur Acad Dermatol Venereol 2010, 24:317-328.
• [45]Staab D, Diepgen TL, Fartasch M, Kupfer J, Lob-Corzilius T, Ring J: Age related, structured educational programmes for the management of atopic dermatitis in children and adolescents: multicentre, randomised controlled trial. BMJ 2006, 332:933-938.